Because mammals lack specific disaccharidases in the small intestine, LOSWIFT™Lactulose transits unchanged to the colon, serving as an energy substrate for saccharolytic bacteria like Lactobacillus acidophilus and Bifidobacterium species. Bacterial fermentation degrades LOSWIFT™Lactulose into short-chain fatty acids (SCFA) such as lactic and formic acids. This acidification lowers intestinal pH, raises osmotic pressure, and increases stool volume. The reduced pH promotes ammonium ion formation, which cannot diffuse through the mucosa, accelerating bowel movement and shortening transit time within 24–48 hours. Compared to direct nerve-stimulating laxatives, LOSWIFT™Lactulose acts safely by modulating colonic motility and peristalsis via organic acidification.

LOSWIFT™Lactulose remains a gold-standard therapeutic option for portal-systemic encephalopathy (PSE). Controlled clinical trials demonstrate that 3 months of LOSWIFT™Lactulose treatment significantly reduces abnormal neuropsychological test results, producing marked improvements in cognitive function, emotional behavior, and overall quality of life. Comparative trials against placebos, lactitol, neomycin, and combination regimens confirm its superior efficacy over placebo and equivalent therapeutic efficacy to neomycin combinations and lactitol in improving mental test performance and systemic clinical symptoms in PSE patients.

Under adequate dietary calcium conditions, LOSWIFT™Lactulose significantly augments the intestinal absorption and retention of essential minerals, including calcium, magnesium, zinc, copper, and iron. Animal models demonstrate increased femoral rupture strength in osteoporosis studies. Stable isotope tracer clinical trials in adult male volunteers show that escalating oral doses of LOSWIFT™Lactulose (2g and 4g) significantly raise urinary stable isotope ratios of ⁴⁴Ca and ²⁵Mg, directly confirming that LOSWIFT™Lactulose enhances human intestinal absorption of both calcium and magnesium.

Oral administration of LOSWIFT™Lactulose generates low-molecular-weight organic acids, significantly reducing faecal pH. This creates optimal conditions for Lactobacillus acidophilus growth, which actively inhibits pathogens like coliforms, Bacteroides, Salmonella, and Shigella. In inflammatory bowel disease (IBD) management—including ulcerative colitis and Crohn's disease—LOSWIFT™Lactulose reduces potential pathogens, limits urinary and respiratory tract infections, decreases gut endotoxin absorption, and regulates bowel habits, offering a safe long-term therapeutic strategy to lower relapse frequency.

LOSWIFT™Lactulose inhibits bacterial ammonia production and draws circulating ammonia from the blood into the colon for faecal excretion. Intestinal acidification suppresses bacterial ammonia-generating enzymes while promoting nitrogen incorporation into bacterial protein biomass. In portacaval shunt models, LOSWIFT™Lactulose significantly lowers postprandial blood ammonia concentrations compared to control groups. Additionally, preoperative oral LOSWIFT™Lactulose administration exhibits strong anti-endotoxin properties, reducing systemic endotoxaemia, lowering creatinine levels, and preventing endotoxin-dependent renal dysfunction in surgical patients.

By stimulating bifidobacteria proliferation and acidifying colonic contents, LOSWIFT™Lactulose profoundly impacts secondary bile acid metabolism. Clinical trials involving middle-aged and elderly individuals receiving 0.3 g/kg LOSWIFT™Lactulose twice daily for 12 weeks demonstrated a significant reduction in both the concentration and total excretion of toxic secondary bile acids, specifically lithocholic acid and deoxycholic acid. Treatment also resulted in increased faecal wet weight, decreased dry weight, and lower faecal pH, attenuating age-related biliary risks.